August 20, 2025 4:44pm

To see some investors taking profits in cell and gene therapy sector stocks ...

Peeking behind the numbers; my covered sector’s Advance/Decline (A/D) line dived again Wednesday 14/19 with 2 flats after Tuesday’s 5/28 and 2 flats following Monday’s 18/17 and 0 flats

After last weeks: 8/15 – Friday - closed positive with 25 positive, 9 negative and 1 flat, 8/14 – Thursday closed barely positive with 18 positive, 17 negative and 0 flat, 8/13 – Wednesday closed positive with 32 positive, 2 negative and 1 flat, 8/12 - Tuesday closed positive with 28 positive, 6 negative and 1 flat and the previous 8/11 – Monday closed negative with 10 positive, 25 negative and 0 flat

My “fact posts” are conveyed with a simplicity of language to highlight what is informative.

Never leave an investor uninformed!  

A sector share pricing comeback is beginning to take shape!

“When you’re riding’ ahead of the sector herd, take a look back every now and then to make sure your share pricing “cows” are moving

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in their portfolio for the short-term

 

Wednesday’s RegMed Investors’ (RMi) pre-open: why write, the sector was a fait accompli, with share pricing still a goner

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

 

Wednesday: The Dow closed UP +16.04 points or +0.04%, the S&P closed DOWN -15.59 points or -0.24% while the Nasdaq closed DOWN -142.095 points or -0.67%

  • Theme of the session, mixed batch of retail earnings and the Fed’s latest meeting minutes release

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  • Fed officials worried at their July meeting about the state of the labor market and inflation, though most agreed that it was too soon to lower interest rates. <minutes release>
  • The meeting summary depicted a divergence of opinion among the central bankers, whose vote to hold their key rate steady came despite objections from two Fed governors who argued in favor of cutting. “Participants generally pointed to risks to both sides of the Committee’s dual mandate, emphasizing upside risk to inflation and downside risk to employment.”
  • Governors Christopher Waller and Bowman voted against the decision to hold rates steady, preferring instead that the Federal Open Market Committee start lowering its key rate.

Wednesday’s advance/decline line opened negative with 5 incliners, 28 decliners and 2 flats ending with a negative close of 14 incliners, 19 decliners and 2 flats

Metrics:  Wednesday, the IBB was up +0.53%, the XBI was up +0.42% while the VIX was up +0.13 points or +0.83% at 15.70

 

Q3 – August – 8 negative and 6 positive closes

  • July – 1 market holiday, 13 positive and 9 negative closes

Q2/25: June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes, May – 1 market holiday, 10 negative and 11 positive closes and April – 11 positive and 10 negative closes

 

Wednesday Closing UP (10 of 14) 

  • Lenz Therapeutics (LENZ +$0.93 after Tuesday’s -$1.16 after Monday’s +$0.92),
  • Supernus Therapeutics (SUPN +$0.68 after Tuesday’s -$0.99 after Monday’s +$0.30),
  • BioLife Solutions (BLFS +$0.42 after Tuesday’s +$0.04 after Monday’s +$0.16),
  • Sarepta Therapeutics (SRPT +$0.40 after Tuesday’s -$0.81 after Monday’s -$0.82),
  • Ionis Pharmaceuticals (IONS +$0.33 after Tuesday’s -$0.95 after Monday’s -$0.35),
  • Ultragenyx Pharmaceuticals (RARE +$0.24 after Tuesday’s -$0.58),
  • AxoGen (AXGN +$0.20),
  • uniQure NV (QURE +$0.15),
  • Compass Therapeutics (CMPX +$0.06),
  • Regenxbio (RGNX +$0.04 after Tuesday’s -$0.68),

Flat (1)

  • Harvard Apparatus RT (OTCQB: HRGN)

Wednesday’s Closing DOWN (10 of 19): 

  • CRISPR Therapeutics (CRSP -$1.09 after Tuesday’s -$3.43 after Monday’s -$2.14),
  • Moderna (MRNA -$1.02),
  • Vericel (VCEL -$0.81),
  • Beam Therapeutics (BEAM -$0.29 after Tuesday’s -$0.75 after Monday’s -$0.72),
  • Voyager Therapeutics (VYGR -$0.21),
  • Cellectis SA (CLLS -$0.16 after Tuesday’s +$0.08),
  • IQV Holdings (IQV -$0.15),
  • Solid Biosciences (SLDB -$0.14),
  • Generation Bio (GBIO -$0.14),
  • Mesoblast (MESO -$0.13 after Tuesday’s -$0.79 after Monday’s -$0.32),

 

The BOTTOM LINE:  Wednesday, the sector was a fait accompli, with share pricing still a goner closing negative.

Reiterating, “Disappointing share pricing download yet, expected … and as I had written, "Uncle algo and his electronic trading dwarfs” are in the house”

Meanwhile, Q2 earnings season is winding down, tks!

The Nasdaq fell 1.4% on Wednesday after it dropped 1.5% Tuesday.  The Nasdaq is on track to fall at least -1% for 2nd day in a row for the 1st time since April 4, when it fell 5.97% and 5.82% yet, market breadth is still considered … solid,

  • I wouldn’t be surprised if the sector pops a bit; with “uncle algo and his electronic trading dwarfs” dip-buying, how much follow-through … will we see in the next round of buying.

The recent selling binge followed a buying spree tailed by a sell-off begets some “ascensions” rewarding post earnings releases with better clinical advances and runways; although some lower highs.

  • From a technical perspective, the next weeks could mark the start of a bearish technical pattern—something we haven’t seen since the spring.”

 

When Fed Chair Powell gives his last speech in Jackson Hole, Wyo., this Friday, this investor will be listening for whether he signals an interest rate cut next month. <some from Yahoo, answers … from me!>

  • But Powell … could lay out more overarching changes to the central bank’s dual mandate that will last long after his tenure is up next May — and mark part of his legacy.
  • I Doubt it, he will have NO legacy!
  • Powell will share his outlook for the economy at Jackson Hole.
  • But he is also expected to lay out changes to the central bank’s policy framework review, which articulates the Fed’s strategy and commitment to fulfilling its congressional mandate for stable prices and maximum employment.
  • His words and strategy will be scrapped …
  • In particular the central bank is expected to drop so-called average inflation targeting, a policy put in place pre-pandemic when inflation was running low and Fed officials wanted to avoid deflation.
  • Forget about it!
  • Bottom line … CUT the rates, Powell will be gone if he doesn’t and the new head will determine the future role of the FED!!
  • Read my words … he is TOAST!!

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

Earnings today: None

  • As earnings slowly come to the last few releases, collaborator revenues and runways has instilled share pricing with forward stability
  • Q2 results so far:  4 net incomes and 25 net losses of 29 releases to date

 

August begins as July ends: understand the “flow” …

  • 8/20 - Wednesday closed negative with 14 positive, 19 negative and 2 flats
  • 8/19 - Tuesday closed negative with 5 positive, 28 negative and 2 flats
  • 8/18 -Monday closed neutral with 18 positive, 17 negative and 0 flat
  • 8/15 – Friday - closed positive with 25 positive, 9 negative and 1 flat
  • 8/14 – Thursday closed barely positive with 18 positive, 17 negative and 0 flat
  • 8/13 – Wednesday closed positive with 32 positive, 2 negative and 1 flat
  • 8/12 - Tuesday closed positive with 28 positive, 6 negative and 1 flat
  • 8/11 – Monday closed negative with 10 positive, 25 negative and 0 flat
  • 8/8 – Friday closed negative with 11 positive, 23 negative and 1 flat
  • 8/7 – Thursday closed negative with 9 positive, 24 negative and 2 flats
  • 8/6 - Wednesday closed negative with 11 positive, 22 negative and 2 flats
  • 8/5 – Tuesday closed negative with 15 positive, 19 negative and 1 flat
  • 8/4 – Monday closed positive with 27 positive, 8 negative and 0 flat
  • 8/1 – Friday closed negative with 9 positive, 20 negative and 6 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in a different role in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Wednesday: Alnylam Pharmaceuticals (ALNY), Supernus Therapeutics (SUPN) and Ionis Pharmaceuticals (IONS)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Precigen (PGEN) and Cellectis SA (CLLS)
  • Monday: Alnylam Pharmaceuticals (ALNY), IQVIA Holdings (IQV) and Lenz Pharmaceuticals (LENZ)
  • Friday: Alnylam Pharmaceuticals (ALNY), IQVIA Holdings (IQV) and Sarepta Therapeutics (SRPT)

The worst three (3) in the session: 

  • Wednesday: CRISPR Therapeutics (CRSP), Moderna (MRNA) and IQVIA Holdings (IQV)
  • Tuesday: CRISPR Therapeutics (CRSP), Lenz Pharmaceuticals (LENZ) and BioNTech (BNTX)
  • Monday: CRISPR Therapeutics (CRSP), BioNTech (BNTX) and Sarepta Therapeutics (SRPT)
  • Friday: Lenz Pharmaceuticals (LENZ), BioLife Solutions (BLFS) and Generation Bio (GBIO)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.